Cited by 106Diabetes Treatment and ManagementDementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Newer glucose‐lowering drugs and risk of dementia: A systematic review and meta‐analysis of observational studies

Open access
Tang, Huilin, Shao, Hui, Shaaban, C. Elizabeth, Yang, Keming, Brown, Joshua, Anton, Stephen, Wu, Yonghui, Bress, Adam +4 more·2023·Journal of the American Geriatrics Society

Abstract

Background: Preclinical studies have suggested potential beneficial effects of newer glucose‐lowering drugs (GLDs) including dipeptidyl peptidase (DPP)‐4 inhibitors, glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs), and sodium glucose co‐transporter‐2 (SGLT2) inhibitors, in protecting humans against cognitive decline and dementia. However, population studies aiming to demonstrate such cognitive benefits from newer GLDs have produced mixed findings. This meta‐analysis aimed to evaluate the association between newer GLDs and risk of dementia in adults with type 2 diabetes (T2D). Methods: Electronic databases were searched up to March 11, 2022 to include observational studies that examined the association between DPP‐4 inhibitors, GLP‐1RAs, and SGLT2 inhibitors and risk of dementia (including all‐cause dementia, Alzheimer's disease [AD], and vascular dementia [VD]) in people with T2D. We conducted a random‐effects meta‐analysis to calculate the relative risk (RR) with 95% confidence interval (CI) for each class of newer GLD. Results: Ten studies (from nine articles) involving 819,511 individuals with T2D were included. Three studies found that SGLT2 inhibitor users had a lower risk of all‐cause dementia than non‐SGLT2 inhibitor users (RR, 0.62; 95% CI, 0.39–0.97). Five studies found that users versus nonusers of GLP‐1RAs were associated with a significant reduction in the risk of all‐cause dementia (RR, 0.72; 95% CI, 0.54–0.97). However, a meta‐analysis for AD and VD was unavailable for SGLT2 inhibitors and GLP‐1RAs because only one study was included for each drug. In seven studies, users vs. nonusers of DPP‐4 inhibitors were significantly associated with a decreased risk of all‐cause dementia (RR, 0.84; 95% CI, 0.74–0.94) and VD (RR, 0.59; 95% CI, 0.47–0.75) but not AD (RR, 0.82; 95% CI, 0.63–1.08). Conclusion: Newer GLDs were associated with a decreased risk of all‐cause dementia in people with T2D. Because of the observational nature and significant heterogeneity between studies, the results should be interpreted with caution. Further research is warranted to confirm our findings.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/jgs.18306

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 56 · Cited by 106

Authors
Tang, H., Shao, H., Shaaban, C. E., Yang, K., Brown, J., Anton, S., Wu, Y., Bress, A., Donahoo, W. T., DeKosky, S. T., Bian, J., & Guo, J.
Affiliations
  • University of Florida Health (US)
  • University of Pittsburgh (US)
  • Harvard University (US)
  • University of Utah (US)
  • University of Florida (US)
Corresponding author
Guo, Jingchuan
Venue
Journal of the American Geriatrics Society
Publisher
Wiley
Published
2023-02-23
Volume
71
Issue
7
Pages
2096-2106
ISSN
  • 0002-8614 (ISSN-L)
  • 1532-5415
OpenAlex
W4321607021
Cited by
106
References
56
Citations by year
2026: 23 · 2025: 42 · 2024: 32 · 2023: 9
FWCI
3.81
Type
journal article
Language
en
Open access
Locations
  • Journal of the American Geriatrics Society (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institutes of Health
  • National Institute on Aging (R56AG069880, K01AG071849, R01AG080991, R01AG076234)
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01DK133465)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
Keywords
dementia risk, type 2 diabetes, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, Alzheimer's disease, vascular dementia, cognitive decline, drug safety, glycemic control, quality of life, cost-effectiveness, health-related quality of life
MeSH terms
Sodium-Glucose Transporter 2 Inhibitors, Dementia, Diabetes Mellitus, Type 2, Glucose, Humans, Hypoglycemic Agents, Dipeptidyl-Peptidase IV Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review